Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, +617

The Lancet Oncology

5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials +8

Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study

Frédéric Amant, Gϋnter von Minckwitz, Sileny Han, +20

Journal of Clinical Oncology

Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer

Gϋnter von Minckwitz, Kathrin Schwedler, Marcus Schmidt, +15

European Journal of Cancer

Breast OncologyMedicinePathologyBreast CancerGbg 26/Big +5

Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial

Volkmar Müller, Stephan Gade, Bettina Steinbach, +10

Breast Cancer Research and Treatment

Tumor BiologyBreast OncologyMedicineGeparquinto TrialTranslational Research Project +7

Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients—a double-blind, randomized study

Sibylle Loibl, Kathrin Schwedler, Gϋnter von Minckwitz, +3

Annals of Oncology

Endocrine OncologyOncologyMetronomic TherapyPharmacologyBreast Cancer +5

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab – Results of the randomised GeparQuinto study (GBG 44)

Jens Huober, Peter A. Fasching, Claus Hanusch, +19

European Journal of Cancer

Breast OncologyGbg 44Breast Cancer PatientsMedicineCancer Management +7

Genetic variants in <scp>VEGF</scp> pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III <scp>G</scp>epar<scp>Q</scp>uinto study

Alexander Hein, Diether Lambrechts, Gϋnter von Minckwitz, +31

International Journal of Cancer

Genetic VariantsVegf Pathway GenesBreast OncologyMedicineImmunology +12

Mitomycin C, 5-fluorouracil and folinic acid (Mi-Fu-Fo) as salvage chemotherapy in breast cancer patients with liver metastases and impaired hepatic function: a phase II study

S. Loibl, Gϋnter von Minckwitz, Kathrin Schwedler, +4

Anti-Cancer Drugs

Breast OncologyMitomycin CMeasurable Liver MetastasesPathologyLiver Dysfunction +14

Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy

Xinrong Guo, Sibylle Loibl, Michael Untch, +13

Breast Care

Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA*

Sibylle Loibl, Dennis Rokitta, Bettina Conrad, +10

Breast Care